



RECEIVED  
JUN 06 2002  
TECH CENTER 18012900  
PATENT

Docket No. 290.0009 0001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Michael S. Kinch et al. ) Group Art Unit: 1642  
Serial No.: 09/640,952 ) Examiner: Natalie A. Davis  
Confirmation No.: 3252 )  
Filed: 17 August 2000 )  
For: EPHA2 AS A DIAGNOSTIC TARGET FOR METASTATIC CANCER (As Amended) 7-3/02

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents  
Washington D.C. 20231

Dear Sir:

In response to the Office Action mailed 2 January 2002, please amend the above-identified application as follows:

In the Specification

Please replace the paragraph beginning at page 2, line 3, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate the changes made.

Identification of increase expression of cell membrane tyrosine kinases would aid in the diagnosis and treatment of metastatic diseases. One such tyrosine kinase in EphA2. A member of the Eph family of tyrosine kinases known as Ephrins, EphA2 is a transmembrane receptor tyrosine kinase with a cell-bound ligand. Although cloned a decade ago, see Lindberg, R.A. and Hunter, T., "cDNA Cloning and Characterization of Eck, an Epithelial Cell Receptor